| Bioactivity | UCI-1 is a SARS-CoV-2 main protease (Mpro) cyclic peptide inhibitor with an IC50 of 160 μM. UCI-1 shows no obvious cytotoxicity at the concentration of inhibiting Mpro. UCI-1 can be used in the study of anti-COVID-19 drugs[1]. |
| Target | IC50: 160 μM (SARS-CoV-2 Mpro) |
| Sequence | cyclo(Lys-Ser-Gln-Phe-{AEPA}) |
| Shortening | cyclo(KSQF-{AEPA}) |
| Formula | C33H45N7O7 |
| Molar Mass | 651.75 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kreutzer AG, et al. A cyclic peptide inhibitor of the SARS-CoV-2 main protease. Eur J Med Chem. 2021 Oct 5;221:113530. |